Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00041
Randall Stafford
{"title":"Vital interconnections between heart and mind","authors":"Randall Stafford","doi":"10.4103/hm.hm-d-23-00041","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00041","url":null,"abstract":"","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"68 1","pages":"199 - 201"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139328388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00054
Fausto Pinto, Doris Yang, Meiyan Liu
{"title":"Prof. Fausto J. Pinto: More of a leading figure and passionate cardiologist","authors":"Fausto Pinto, Doris Yang, Meiyan Liu","doi":"10.4103/hm.hm-d-23-00054","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00054","url":null,"abstract":"","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"10 1","pages":"255 - 259"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139326291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00059
Lin Lu
{"title":"Short- and long-term effects of COVID-19 on psychological and cardiovascular functions","authors":"Lin Lu","doi":"10.4103/hm.hm-d-23-00059","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00059","url":null,"abstract":"","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"67 1","pages":"197 - 198"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139325809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00038
Mark Faghy, Ruth M. Ashton
The COVID-19 pandemic has been one of the largest risks to global population health in recent years, and acute infection and the persistent symptoms of long COVID will likely continue to affect global health for years to come. Long COVID is very complex and impacts multiple systems and organs, resulting in an extensive and undulating presentation of symptoms. COVID-19 has been shown to cause various cardiovascular (CV) injuries following acute infection, with many patients suffering long-lasting impairment. This review article discusses the prevalence of CV complications following an acute COVID-19 infection and considers effective prevention and disease management strategies to help restore functional status and quality of life in patients.
{"title":"A narrative review on increased prevalence of cardiovascular complications following a COVID-19 infection: The risks and considerations for effective management and practice","authors":"Mark Faghy, Ruth M. Ashton","doi":"10.4103/hm.hm-d-23-00038","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00038","url":null,"abstract":"The COVID-19 pandemic has been one of the largest risks to global population health in recent years, and acute infection and the persistent symptoms of long COVID will likely continue to affect global health for years to come. Long COVID is very complex and impacts multiple systems and organs, resulting in an extensive and undulating presentation of symptoms. COVID-19 has been shown to cause various cardiovascular (CV) injuries following acute infection, with many patients suffering long-lasting impairment. This review article discusses the prevalence of CV complications following an acute COVID-19 infection and considers effective prevention and disease management strategies to help restore functional status and quality of life in patients.","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"5 1","pages":"202 - 206"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139326607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00028
Xuyao Han, Ying Liu, Guangping Li, Gary Tse, Tong Liu
Based on glucose levels, people fall into three groups, normal individuals, prediabetic patients, and diabetic mellitus (DM) patients. Prediabetes (pre-DM) is an intermediate condition that exists between normal glucose levels and DM. Atrial fibrillation (AF), one of the most prevalent cardiac arrhythmias in medical practice, contributes to a considerable morbidity and mortality rate. In this review, we looked at the clinical symptoms, pathological alterations, molecular mechanisms, and associated risk factors of pre-DM, type 2 DM (T2DM), and AF. In clinical practice, pre-DM can increase the prevalence of AF. In the hyperglycemic state, oxidative stress, inflammation, and endoplasmic reticulum stress can cause alterations in atrial cell or cardiac fibroblast function through tumor necrosis factor-α/nuclear factor-κB (NF-κB)/transforming growth factor-β, mitogen-activated protein kinase-matrix metalloproteinase-9 and PARP-1 is poly (ADP-ribose) polymerase 1. IκB kinase-α/NF-κB pathways, and further cause atria undergo structural, electrical, and neural remodeling which lead to the occurrence and persistence of AF. In addition, pre-DM and T2DM may worsen as a result of obesity, obstructive sleep apnea, and arterial hypertension. Furthermore, clinical researches have demonstrated that lifestyle interventions and/or pharmacotherapy in pre-DM patients can effectively delay the progresssion of pre-DM to T2DM. Individualized glycemic management and AF management should be provided to AF patients with pre-DM or DM.
{"title":"A narrative review on prediabetes or diabetes and atrial fibrillation: From molecular mechanisms to clinical practice","authors":"Xuyao Han, Ying Liu, Guangping Li, Gary Tse, Tong Liu","doi":"10.4103/hm.hm-d-23-00028","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00028","url":null,"abstract":"Based on glucose levels, people fall into three groups, normal individuals, prediabetic patients, and diabetic mellitus (DM) patients. Prediabetes (pre-DM) is an intermediate condition that exists between normal glucose levels and DM. Atrial fibrillation (AF), one of the most prevalent cardiac arrhythmias in medical practice, contributes to a considerable morbidity and mortality rate. In this review, we looked at the clinical symptoms, pathological alterations, molecular mechanisms, and associated risk factors of pre-DM, type 2 DM (T2DM), and AF. In clinical practice, pre-DM can increase the prevalence of AF. In the hyperglycemic state, oxidative stress, inflammation, and endoplasmic reticulum stress can cause alterations in atrial cell or cardiac fibroblast function through tumor necrosis factor-α/nuclear factor-κB (NF-κB)/transforming growth factor-β, mitogen-activated protein kinase-matrix metalloproteinase-9 and PARP-1 is poly (ADP-ribose) polymerase 1. IκB kinase-α/NF-κB pathways, and further cause atria undergo structural, electrical, and neural remodeling which lead to the occurrence and persistence of AF. In addition, pre-DM and T2DM may worsen as a result of obesity, obstructive sleep apnea, and arterial hypertension. Furthermore, clinical researches have demonstrated that lifestyle interventions and/or pharmacotherapy in pre-DM patients can effectively delay the progresssion of pre-DM to T2DM. Individualized glycemic management and AF management should be provided to AF patients with pre-DM or DM.","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"32 1","pages":"207 - 216"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139325836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00037
Harriet Lomholt-Welch, A. Morrow, R. Sykes, Merna Saleh, Baryab Zahra, Alasdair MacIntosh, Anna Kamdar, Catherine Bagot, Hannah Bayes, Kevin Blyth, H. Bulluck, D. Carrick, Colin Church, D. Corcoran, Iain Findlay, V. Gibson, L. Gillespie, D. Grieve, Pauline Barrientos, Antonia Ho, Ninian N Lang, David Lowe, V. Lennie, Peter Macfarlane, Kaitlin J. Mayne, Patrick B. Mark, A. Mcconnachie, R. McGeoch, Sabrina Nordin, Alexander Payne, Alastair Rankin, K. Robertson, N. Ryan, Giles Roditi, Naveed Sattar, D. Stobo, Sarah Allwood-Spiers, R. Touyz, G. Veldtman, S. Weeden, R. Weir, S. Watkins, P. Welsh, K. Mangion, Colin Berry
Background: The multisystem associations between baseline mental health status and coronavirus disease-19 (COVID)-19 illness trajectory are uncertain. Objectives: This article will investigate the associations between baseline mental health status and disease trajectory following COVID-19 hospitalization, which may have implications for practice and future research. Methods: The Chief Scientist Office Cardiovascular and Pulmonary Imaging in severe acute respiratory syndrome (SARS) COVID-19 study is a prospective, observational, multicenter, longitudinal, secondary care cohort study that assessed the time-course of multi-organ injury in posthospital survivors of COVID-19. Patients were assessed in-hospital, at 28–60 days after discharge and in the longer term using electronic health record linkage. Results: One hundred and fifty-two patients (mean ± standard deviation [SD] age 54.3 ± 11.8 years, 43% female, 40% most socio-economically deprived quintile, 33% history of mental health history) were enrolled and had mental health serially assessed using the Patient Health Questionnaire-4 (PHQ-4) questionnaire. Fifty-three (35%) had PHQ-4 score of 6–12 consistent with moderate-severe symptoms of anxiety or depression and this was associated with diagnostic criteria for myocarditis (P = 0.0498). Moderate-severe symptoms of anxiety or depression were positively associated with higher perception of illness, lower health-related quality of life (HRQoL), and poorer physical function. The mean (SD) duration of follow-up after hospital discharge was 428 (86) days (range, 290–627 days). PHQ-4 score was not associated with clinical outcomes at follow-up. Conclusions: In patients who have been hospitalized with COVID-19, moderate-severe symptoms of anxiety or depression were associated with myocarditis, worse HRQoL, higher perception of illness, and lower levels of physical function. Public Registration: ClinicalTrials.gov identifier is NCT04403607.
{"title":"Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study","authors":"Harriet Lomholt-Welch, A. Morrow, R. Sykes, Merna Saleh, Baryab Zahra, Alasdair MacIntosh, Anna Kamdar, Catherine Bagot, Hannah Bayes, Kevin Blyth, H. Bulluck, D. Carrick, Colin Church, D. Corcoran, Iain Findlay, V. Gibson, L. Gillespie, D. Grieve, Pauline Barrientos, Antonia Ho, Ninian N Lang, David Lowe, V. Lennie, Peter Macfarlane, Kaitlin J. Mayne, Patrick B. Mark, A. Mcconnachie, R. McGeoch, Sabrina Nordin, Alexander Payne, Alastair Rankin, K. Robertson, N. Ryan, Giles Roditi, Naveed Sattar, D. Stobo, Sarah Allwood-Spiers, R. Touyz, G. Veldtman, S. Weeden, R. Weir, S. Watkins, P. Welsh, K. Mangion, Colin Berry","doi":"10.4103/hm.hm-d-23-00037","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00037","url":null,"abstract":"Background: The multisystem associations between baseline mental health status and coronavirus disease-19 (COVID)-19 illness trajectory are uncertain. Objectives: This article will investigate the associations between baseline mental health status and disease trajectory following COVID-19 hospitalization, which may have implications for practice and future research. Methods: The Chief Scientist Office Cardiovascular and Pulmonary Imaging in severe acute respiratory syndrome (SARS) COVID-19 study is a prospective, observational, multicenter, longitudinal, secondary care cohort study that assessed the time-course of multi-organ injury in posthospital survivors of COVID-19. Patients were assessed in-hospital, at 28–60 days after discharge and in the longer term using electronic health record linkage. Results: One hundred and fifty-two patients (mean ± standard deviation [SD] age 54.3 ± 11.8 years, 43% female, 40% most socio-economically deprived quintile, 33% history of mental health history) were enrolled and had mental health serially assessed using the Patient Health Questionnaire-4 (PHQ-4) questionnaire. Fifty-three (35%) had PHQ-4 score of 6–12 consistent with moderate-severe symptoms of anxiety or depression and this was associated with diagnostic criteria for myocarditis (P = 0.0498). Moderate-severe symptoms of anxiety or depression were positively associated with higher perception of illness, lower health-related quality of life (HRQoL), and poorer physical function. The mean (SD) duration of follow-up after hospital discharge was 428 (86) days (range, 290–627 days). PHQ-4 score was not associated with clinical outcomes at follow-up. Conclusions: In patients who have been hospitalized with COVID-19, moderate-severe symptoms of anxiety or depression were associated with myocarditis, worse HRQoL, higher perception of illness, and lower levels of physical function. Public Registration: ClinicalTrials.gov identifier is NCT04403607.","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"59 1","pages":"235 - 245"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139327373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00033
Wei Yan, Shuyu Ni, Chang Liu, Junliang Yuan, Yimiao Zhao, Na Zeng, Huan Mei, Shuilin Wu, Jianyu Que, K. Yuan, Le Shi, Siwei Sun, Shiqiu Meng, Maosheng Ran, Y. Leng, Arun Ravindran, Jie Shi, Yanping Bao, Lin Lu
Background: The coronavirus disease-2019 (COVID-19) pandemic worldwide has caused a high burden of mental problems, which may be associated with subjective cognitive impairment in the general population. Objectives: This cross-sectional survey aimed to investigate the level and pattern of cognitive failure (CF) and its negative changes during the COVID-19 pandemic among the general population in China. Methods: The participants completed an online questionnaire between April 18 and May 4, 2020, and those aged between 18 and 70 were included in this study. CF was measured using the 14-item CF Questionnaire (CFQ-14). Factors associated with CF and negative changes in CF were evaluated using multiple linear and logistic regression models. A total of 30,879 eligible participants were recruited; most were female (59.10%) and aged 31–45 (61.51%). Results: The mean CFQ-14 score was 15.62 (standard deviation = 11.55), and 4,619 (14.96%) participants reported negative changes in CF during the pandemic. Multiple regression analyses showed that participants with female gender, history of physical and mental disease, the self-perceived influence of COVID-19, altered appetite and taste preference, worse interpersonal relationships, long sleep duration, poor sleep quality, depressive, anxiety and posttraumatic stress disorder symptoms had a higher level of CF and negative CF changes, while regular exercise was associated with a lower risk of both outcomes. Conclusions: This study indicates that CF symptoms should be monitored in the general population during pandemics. A healthy lifestyle and reduction in psychological stress could help promote normal cognitive function during pandemics.
{"title":"Pattern and associated factors of cognitive failures in the general chinese population during the early stages of the COVID-19 pandemic: A cross-sectional study","authors":"Wei Yan, Shuyu Ni, Chang Liu, Junliang Yuan, Yimiao Zhao, Na Zeng, Huan Mei, Shuilin Wu, Jianyu Que, K. Yuan, Le Shi, Siwei Sun, Shiqiu Meng, Maosheng Ran, Y. Leng, Arun Ravindran, Jie Shi, Yanping Bao, Lin Lu","doi":"10.4103/hm.hm-d-23-00033","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00033","url":null,"abstract":"Background: The coronavirus disease-2019 (COVID-19) pandemic worldwide has caused a high burden of mental problems, which may be associated with subjective cognitive impairment in the general population. Objectives: This cross-sectional survey aimed to investigate the level and pattern of cognitive failure (CF) and its negative changes during the COVID-19 pandemic among the general population in China. Methods: The participants completed an online questionnaire between April 18 and May 4, 2020, and those aged between 18 and 70 were included in this study. CF was measured using the 14-item CF Questionnaire (CFQ-14). Factors associated with CF and negative changes in CF were evaluated using multiple linear and logistic regression models. A total of 30,879 eligible participants were recruited; most were female (59.10%) and aged 31–45 (61.51%). Results: The mean CFQ-14 score was 15.62 (standard deviation = 11.55), and 4,619 (14.96%) participants reported negative changes in CF during the pandemic. Multiple regression analyses showed that participants with female gender, history of physical and mental disease, the self-perceived influence of COVID-19, altered appetite and taste preference, worse interpersonal relationships, long sleep duration, poor sleep quality, depressive, anxiety and posttraumatic stress disorder symptoms had a higher level of CF and negative CF changes, while regular exercise was associated with a lower risk of both outcomes. Conclusions: This study indicates that CF symptoms should be monitored in the general population during pandemics. A healthy lifestyle and reduction in psychological stress could help promote normal cognitive function during pandemics.","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"8 1","pages":"224 - 234"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139327257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00015
H. Jahrami, Zahra Saif, Khaled Trabelsi, S. Pandi‑Perumal, Mary V. Seeman
Background and Aims: There has been no previous investigation into the relationship between serum β-Carotene levels and metabolic syndrome in patients with schizophrenia. This research aims to explore the association between schizophrenia, metabolic syndrome, and serum β-Carotene levels. Specifically, this study addresses this knowledge gap and examines whether lower serum β-Carotene levels are associated with an increased risk for metabolic syndrome in patients with schizophrenia. Methods and Results: The present study involved 38 patients with schizophrenia (n = 38). We collected demographic data, anthropometric measurements, blood samples for lipid panels, sugar levels, and serum β-Carotene levels, as well as participant responses to food frequency questionnaires. Results revealed the median serum β-Carotene was 0.87 (range: 0.69–1.14 μmol/L). The median metabolic syndrome Z-score using waist circumference was 0.13 (range: −1.10–2.39). Pairwise Spearman's correlation between metabolic syndrome Z-score versus β-Carotene showed a rho = −0.56, P < 0.001 for the overall sample. Linear regression between metabolic syndrome Z-score as a dependent variable and serum β-Carotene as an independent variable showed a regression coefficient of −3.11, P < 0.001. Conclusion: The findings of this study offer suggestive evidence of a statistically significant positive correlation between reduced serum β-Carotene levels in individuals with schizophrenia and a heightened global risk of developing metabolic syndrome. This preliminary study has implications for the management of schizophrenia patients, suggesting that patients' serum levels of β-Carotene be periodically checked and referrals made to dieticians as necessary.
研究背景和目的：目前还没有关于精神分裂症患者血清β-胡萝卜素水平与代谢综合征之间关系的研究。本研究旨在探讨精神分裂症、代谢综合征和血清β-胡萝卜素水平之间的关系。具体而言，本研究针对这一知识空白，探讨血清β-胡萝卜素水平较低是否与精神分裂症患者代谢综合征风险增加有关。方法和结果：本研究涉及 38 名精神分裂症患者（n = 38）。我们收集了人口统计学数据、人体测量数据、血脂样本、血糖水平、血清β-胡萝卜素水平以及参与者对食物频率问卷的回答。结果显示，血清β-胡萝卜素的中位数为 0.87（范围：0.69-1.14 μmol/L）。使用腰围计算的代谢综合征 Z 值中位数为 0.13（范围：-1.10-2.39）。代谢综合征 Z 评分与 β-胡萝卜素之间的配对 Spearman 相关性显示，总体样本的 rho = -0.56，P < 0.001。代谢综合征 Z 评分作为因变量，血清 β-胡萝卜素作为自变量，两者之间的线性回归显示回归系数为 -3.11，P <0.001。结论本研究的结果提供了提示性证据，表明精神分裂症患者血清中β-胡萝卜素水平的降低与代谢综合征发病风险的增加之间存在统计学意义上的显著正相关。这项初步研究对精神分裂症患者的管理具有重要意义，建议定期检查患者血清中的β-胡萝卜素水平，并在必要时将患者转介给营养师。
{"title":"Exploring the association between serum β-Carotene and metabolic syndrome in patients with schizophrenia","authors":"H. Jahrami, Zahra Saif, Khaled Trabelsi, S. Pandi‑Perumal, Mary V. Seeman","doi":"10.4103/hm.hm-d-23-00015","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00015","url":null,"abstract":"Background and Aims: There has been no previous investigation into the relationship between serum β-Carotene levels and metabolic syndrome in patients with schizophrenia. This research aims to explore the association between schizophrenia, metabolic syndrome, and serum β-Carotene levels. Specifically, this study addresses this knowledge gap and examines whether lower serum β-Carotene levels are associated with an increased risk for metabolic syndrome in patients with schizophrenia. Methods and Results: The present study involved 38 patients with schizophrenia (n = 38). We collected demographic data, anthropometric measurements, blood samples for lipid panels, sugar levels, and serum β-Carotene levels, as well as participant responses to food frequency questionnaires. Results revealed the median serum β-Carotene was 0.87 (range: 0.69–1.14 μmol/L). The median metabolic syndrome Z-score using waist circumference was 0.13 (range: −1.10–2.39). Pairwise Spearman's correlation between metabolic syndrome Z-score versus β-Carotene showed a rho = −0.56, P < 0.001 for the overall sample. Linear regression between metabolic syndrome Z-score as a dependent variable and serum β-Carotene as an independent variable showed a regression coefficient of −3.11, P < 0.001. Conclusion: The findings of this study offer suggestive evidence of a statistically significant positive correlation between reduced serum β-Carotene levels in individuals with schizophrenia and a heightened global risk of developing metabolic syndrome. This preliminary study has implications for the management of schizophrenia patients, suggesting that patients' serum levels of β-Carotene be periodically checked and referrals made to dieticians as necessary.","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"7 1","pages":"264 - 269"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139330006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-01DOI: 10.4103/hm.hm-d-23-00043
Daniel Caldeira, Joana Brito, Catarina Gregório, Rui Plácido, Fausto Pinto
The COVID-19 pandemic had profound implications for patients with cardiovascular diseases (CVDs), both in the short- and long-term. In this article, we provide an overview of the effects of the pandemic on individuals with preexisting cardiovascular conditions. In the short term, the severe acute respiratory syndrome coronavirus 2 infection increased the risk of many cardiovascular events. Furthermore, the pandemic has disrupted health-care systems worldwide, leading to constraints in routine care, and limited access to specialized cardiovascular services and procedure. This has resulted in increased morbidity and mortality rates among patients with CVD (coronary artery disease, hypertrophic cardiomyopathy, heart failure (HF), heart transplant recipients, atrial fibrillation, atrial flutter, previous stroke, or previous peripheral artery disease). In the long term, the COVID-19 impact on patients with CVD extends beyond the acute phase of the disease. Studies have highlighted the development of long-term cardiovascular complications in COVID-19 survivors, such as acute coronary syndrome myocarditis, HF, stroke, venous thromboembolism, and arrhythmias, which may lead to a surge of new cases associated with CVD in the postpandemic era. Health-care systems must prioritize cardiovascular care, developing strategies to identify the patients at higher risk and provide the care to minimize the impact of the pandemic on patients with CVD.
{"title":"Short- and long-term effects of the COVID-19 pandemic on patients with cardiovascular diseases: A mini-review","authors":"Daniel Caldeira, Joana Brito, Catarina Gregório, Rui Plácido, Fausto Pinto","doi":"10.4103/hm.hm-d-23-00043","DOIUrl":"https://doi.org/10.4103/hm.hm-d-23-00043","url":null,"abstract":"The COVID-19 pandemic had profound implications for patients with cardiovascular diseases (CVDs), both in the short- and long-term. In this article, we provide an overview of the effects of the pandemic on individuals with preexisting cardiovascular conditions. In the short term, the severe acute respiratory syndrome coronavirus 2 infection increased the risk of many cardiovascular events. Furthermore, the pandemic has disrupted health-care systems worldwide, leading to constraints in routine care, and limited access to specialized cardiovascular services and procedure. This has resulted in increased morbidity and mortality rates among patients with CVD (coronary artery disease, hypertrophic cardiomyopathy, heart failure (HF), heart transplant recipients, atrial fibrillation, atrial flutter, previous stroke, or previous peripheral artery disease). In the long term, the COVID-19 impact on patients with CVD extends beyond the acute phase of the disease. Studies have highlighted the development of long-term cardiovascular complications in COVID-19 survivors, such as acute coronary syndrome myocarditis, HF, stroke, venous thromboembolism, and arrhythmias, which may lead to a surge of new cases associated with CVD in the postpandemic era. Health-care systems must prioritize cardiovascular care, developing strategies to identify the patients at higher risk and provide the care to minimize the impact of the pandemic on patients with CVD.","PeriodicalId":34653,"journal":{"name":"Heart and Mind","volume":"3 1","pages":"217 - 223"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139325938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：